ReviewDrugs in context2026

Recombinant human erythropoietin therapy in patients with cancer: efficacy, risks and the controversy of EpoR expression.

Alessio Sturiale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.